Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Susan G. Komen Breast Cancer Foundation
Daiichi-Sankyo Pharma Development
Triple Negative Breast Cancer Foundation
Information provided by (Responsible Party):
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT01307891
First received: March 1, 2011
Last updated: May 31, 2014
Last verified: May 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)